(Total Views: 558)
Posted On: 09/30/2020 8:11:15 PM
Post# of 154567
Re: nothingspecial #58766
Totally agree with your perspective, nothingspecial.
How is it possible that Remdesiver gets an efficacy stop with a meager four out of 11 day hospital stay reduction and Leronlimab cannot get an efficacy stop with 20, 30, or even 50 percent mortality reduction?
I think the answer to this question is: Remedisivir achieved efficacy stop on a trial with 1300 patients and Leronlimab will not achieve stop with 195 patients.
p-values calculated by statistical mathematics are a strong function of the number of patients in the calculation.
I believe that is by far the most significant difference between the Remdesivir and Leronlimab trials.
The stat math tilts very heavily in favor of the company that has enough cash to enroll thousands of patients.
How is it possible that Remdesiver gets an efficacy stop with a meager four out of 11 day hospital stay reduction and Leronlimab cannot get an efficacy stop with 20, 30, or even 50 percent mortality reduction?
I think the answer to this question is: Remedisivir achieved efficacy stop on a trial with 1300 patients and Leronlimab will not achieve stop with 195 patients.
p-values calculated by statistical mathematics are a strong function of the number of patients in the calculation.
I believe that is by far the most significant difference between the Remdesivir and Leronlimab trials.
The stat math tilts very heavily in favor of the company that has enough cash to enroll thousands of patients.
(1)
(0)
